Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HYPD NASDAQ:IMDX NASDAQ:LFCR NASDAQ:OKUR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHYPDHyperion DeFi$3.11$3.47$2.49▼$16.35$47.14M2.49737,759 shs425,842 shsIMDXOncocyte$5.74$5.47$2.33▼$8.51$185.35M1.76235,683 shs141,945 shsLFCRLifecore Biomedical$5.09$5.13$3.63▼$8.98$190.92M1.06230,085 shs121,549 shsOKUROnKure Therapeutics$4.58$4.22$1.91▼$5.38$185.01M0.27472,497 shs222,298 shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHYPDHyperion DeFi0.00%+2.81%-13.85%-4.31%-80.34%IMDXOncocyte0.00%+6.30%-4.81%+52.66%+573,999,900.00%LFCRLifecore Biomedical0.00%-1.55%-10.23%+32.55%-36.69%OKUROnKure Therapeutics0.00%+1.78%+9.05%+6.76%+90.83%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHYPDHyperion DeFi$3.11$3.47$2.49▼$16.35$47.14M2.49737,759 shs425,842 shsIMDXOncocyte$5.74$5.47$2.33▼$8.51$185.35M1.76235,683 shs141,945 shsLFCRLifecore Biomedical$5.09$5.13$3.63▼$8.98$190.92M1.06230,085 shs121,549 shsOKUROnKure Therapeutics$4.58$4.22$1.91▼$5.38$185.01M0.27472,497 shs222,298 shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHYPDHyperion DeFi0.00%+2.81%-13.85%-4.31%-80.34%IMDXOncocyte0.00%+6.30%-4.81%+52.66%+573,999,900.00%LFCRLifecore Biomedical0.00%-1.55%-10.23%+32.55%-36.69%OKUROnKure Therapeutics0.00%+1.78%+9.05%+6.76%+90.83%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHYPDHyperion DeFi 2.00Hold$6.95123.47% UpsideIMDXOncocyte 2.00Hold$12.00109.06% UpsideLFCRLifecore Biomedical 1.75Reduce$6.5027.70% UpsideOKUROnKure Therapeutics 2.00Hold$27.00489.52% UpsideCurrent Analyst Ratings BreakdownLatest HYPD, LFCR, OKUR, and IMDX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2026HYPDHyperion DeFi Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$4.00 ➝ $6.606/30/2026LFCRLifecore Biomedical Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell6/24/2026HYPDHyperion DeFi Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/24/2026IMDXOncocyte Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/16/2026LFCRLifecore Biomedical Barrington ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$6.00 ➝ $6.506/8/2026HYPDHyperion DeFi Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$8.25 ➝ $7.305/29/2026OKUROnKure Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/20/2026HYPDHyperion DeFi Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/11/2026OKUROnKure Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/7/2026LFCRLifecore Biomedical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)5/7/2026OKUROnKure Therapeutics JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 7/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHYPDHyperion DeFi$810K58.21N/AN/A$4.73 per share0.66IMDXOncocyte$4.05M45.76N/AN/A($1.10) per share-5.22LFCRLifecore Biomedical$128.87M1.48N/AN/A$0.42 per share12.12OKUROnKure TherapeuticsN/AN/AN/AN/A$4.11 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHYPDHyperion DeFi-$45.31M-$9.95N/A2.70N/AN/A-91.59%-73.08%N/AIMDXOncocyte-$50.22M-$1.48N/AN/AN/A-2,454.64%N/A-96.96%N/ALFCRLifecore BiomedicalN/A-$0.94N/AN/AN/A-25.43%N/A-14.40%8/5/2026 (Estimated)OKUROnKure Therapeutics-$59.52M-$4.33N/AN/AN/AN/A-61.02%-55.99%8/11/2026 (Estimated)Latest HYPD, LFCR, OKUR, and IMDX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/31/2026N/ALFCRLifecore Biomedical-$0.2450N/AN/AN/A$30.08 millionN/A5/13/2026Q1 2026IMDXOncocyteN/A-$0.28N/A-$0.12N/A$0.03 million5/6/2026Q1 2026LFCRLifecore Biomedical-$0.29-$0.43-$0.14-$0.43$25.96 million$23.19 million5/5/2026Q1 2026OKUROnKure Therapeutics-$0.7425-$1.11-$0.3675-$1.11$0.17 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthHYPDHyperion DeFiN/AN/AN/AN/AN/AIMDXOncocyteN/AN/AN/AN/AN/ALFCRLifecore BiomedicalN/AN/AN/AN/AN/AOKUROnKure TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHYPDHyperion DeFi0.121.971.97IMDXOncocyteN/A2.542.51LFCRLifecore BiomedicalN/A3.792.41OKUROnKure TherapeuticsN/A13.7813.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHYPDHyperion DeFi25.84%IMDXOncocyte55.35%LFCRLifecore Biomedical83.36%OKUROnKure Therapeutics90.98%Insider OwnershipCompanyInsider OwnershipHYPDHyperion DeFi7.50%IMDXOncocyte2.21%LFCRLifecore Biomedical32.68%OKUROnKure Therapeutics2.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHYPDHyperion DeFi4015.16 million14.02 millionNo DataIMDXOncocyte12032.29 million31.58 millionN/ALFCRLifecore Biomedical69037.51 million25.25 millionOptionableOKUROnKure TherapeuticsN/A40.40 million39.47 millionN/AHYPD, LFCR, OKUR, and IMDX HeadlinesRecent News About These CompaniesOnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Kα Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026July 2 at 8:00 AM | globenewswire.comOnKure Therapeutics (NASDAQ:OKUR) Trading Up 1.3% - Still a Buy?July 1 at 2:22 AM | americanbankingnews.comOnKure Therapeutics, Inc. Class AJune 9, 2026 | edition.cnn.comOnKure Shareholders Approve Amended 2024 Equity Incentive PlanJune 4, 2026 | tipranks.comOnkure Therapeutics (OKUR) Stock Forecast & Price TargetMay 22, 2026 | investing.comOnKure Therapeutics (OKUR) Receives a Buy from OppenheimerMay 8, 2026 | theglobeandmail.comOnKure Therapeutics war chest nears $200M following spring stock saleMay 6, 2026 | bizwest.comBOnKure Therapeutics Reports First Quarter 2026 Financial ResultsMay 5, 2026 | globenewswire.comOnKure Therapeutics (OKUR) price target decreased by 15.13% to 20.60April 28, 2026 | msn.comOnKure Therapeutics (OKUR) Gets a Buy from JonesTradingApril 26, 2026 | theglobeandmail.comOnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and ...March 27, 2026 | finance.yahoo.comOnKure to sell $150M in stock to fund drug developmentMarch 27, 2026 | bizwest.comBOnKure Therapeutics Announces Oversubscribed $150 Million Private Placement to Advance Next-Generation PI3Kα Pan-Mutant Selective Inhibitor Candidates in Breast Cancer and Vascular AnomaliesMarch 27, 2026 | globenewswire.comOnKure reports nearly $60M cash on hand as drug trials continueMarch 19, 2026 | bizwest.comBOnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial ResultsMarch 12, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG), OnKure Therapeutics (OKUR) and Praxis Precision Medicines (PRAX)January 24, 2026 | theglobeandmail.comOnKure Therapeutics (OKUR) Price Target Decreased by 10.00% to 27.54November 18, 2025 | msn.comOnKure Therapeutics Announces Sales Agreement with LeerinkNovember 13, 2025 | theglobeandmail.comOnKure Therapeutics reports Q3 EPS ($1.09), consensus ($1.20)November 7, 2025 | msn.comOnKure Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Business UpdateNovember 6, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHYPD, LFCR, OKUR, and IMDX Company DescriptionsHyperion DeFi NASDAQ:HYPD$3.11 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$3.07 -0.04 (-1.25%) As of 07/2/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.Oncocyte NASDAQ:IMDX$5.74 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$5.60 -0.14 (-2.42%) As of 07/2/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.Lifecore Biomedical NASDAQ:LFCR$5.09 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$5.16 +0.07 (+1.39%) As of 07/2/2026 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.OnKure Therapeutics NASDAQ:OKUR$4.58 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$4.58 +0.00 (+0.11%) As of 07/2/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.OnKure Therapeutics, Inc. engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. It is headquartered in Boulder, CO. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Why the Comcast Spin-Off Won't Fix What's Actually Broken Shorting the Grid: Bloom Energy’s $25B AI Power Play AST SpaceMobile’s Japan Catalyst Puts Its Rollout Story Back in Focus Why Kroger's Giant Eagle Deal Could Change Everything SMRs Spark a Chain Reaction for Nano Nuclear Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
